The live attenuated chic書答kenpox vaccine of BCHT is suitable f路章or all healthy chickenpox susceptible p快和ersons over 12 months 一國of age. After being vac黃音cinated, it can stimulate th美可e body to develop immunity again答水st chickenpox-zos員房ter virus, thereby preventin校快g chickenpox. This produ畫空ct uses the widely used Oka strain 頻北as the varicella vaccine strain. The動紅 vaccine lyophilizat月制ion protection agent indep雪筆endently developed by the company is 和兒used as the lyo員腦philization prote校站ction solution. It is the first vacci商他ne to remove animal-deriv討問ed gelatin in Chi說視na and is also the first 3來刀6-month live atten南會uated varicella vaccine to be appr能都oved in the world, which 算朋not only solves the stability務喝 problems faced in the 些事production, transportation, and storage妹又 of the vaccine, b討秒ut also reduces the irritati從紙on to the human body and improv朋林es safety. In 2018, the pr醫光oduct successfully completed the做麗 technical upgra國問de of the cell fac舞開tory process, and the technica火地l level has reached the domest數煙ic leading level, which has f章友urther improved the product quality.

The live attenuat哥我ed chickenpox vaccine o她少f BCHT currently applied for 5麗姐 invention patent子體s, including 1 Chinese patent, 4 inter新技national patents; 2 appearance patent物新s for products and anc錢又illary products, and 1 utility model鐵呢 patent for ancillary produ空劇cts. In 2018, the company's live 老得attenuated chicke身票npox vaccine achieved sales r志北evenue of 880 million RMB件微, and its domestic market share 煙機reached nearly 40%.